Bayer (BAYRY) announced that the FDA has approved Hyrnuo, an oral, reversible, tyrosine kinase inhibitor for the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer whose tumors have HER2 tyrosine kinase domain activating mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BAYRY:
- FDA grants accelerated approval to sevabertinib for non-squamous non-small cell
- Galmed’s Aramchol and Bayer’s Stivarga show synergistic effect in GI cancers
- Bayer price target raised to EUR 30.40 from EUR 26 at Berenberg
- Bayer AG Earnings Call: Growth Amid Challenges
- Bayer CFO says ‘general market growth trends intact’ for Consumer Health